
HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00.
Shares of Atara Biotherapeutics are trading down 3.1% over the last 24 hours, at $5.00 per share.

HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00.
Shares of Atara Biotherapeutics are trading down 3.1% over the last 24 hours, at $5.00 per share.